Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7550984,detection limit,The assay allowed the simultaneous determination of all analytes in 1 ml of urine and the detection limit was 2 ng/ml with a signal-to-noise ratio of 3.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),[ng] / [ml],2,6147,DB00231,Temazepam
,7550984,signal-to-noise ratio,The assay allowed the simultaneous determination of all analytes in 1 ml of urine and the detection limit was 2 ng/ml with a signal-to-noise ratio of 3.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),,3,6148,DB00231,Temazepam
>,7550984,Recoveries,Recoveries of the analytes and the internal standard (prazepam) were > 82%.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,82,6149,DB00231,Temazepam
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,3.9,6150,DB00231,Temazepam
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,6.6,6151,DB00231,Temazepam
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,2.8,6152,DB00231,Temazepam
,6127197,time to peak,Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours.,"Temazepam (Restoril, Sandoz Pharmaceuticals). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127197/),h,2.99,10627,DB00231,Temazepam
,6127197,elimination half-life,Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours.,"Temazepam (Restoril, Sandoz Pharmaceuticals). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127197/),h,14.7,10628,DB00231,Temazepam
,3930095,limit of detection,The limit of detection in serum is about 10 micrograms/L for each drug.,"Liquid-chromatographic assay of diazepam and its major metabolites in serum, and application to pharmacokinetic study of high doses of diazepam in schizophrenics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3930095/),[μg] / [l],10,15853,DB00231,Temazepam
,3930095,Analytical recovery,"Analytical recovery of each drug added to the serum varied from 91 to 102% for oxazepam and temazepam, from 82 to 99% for nordiazepam and diazepam.","Liquid-chromatographic assay of diazepam and its major metabolites in serum, and application to pharmacokinetic study of high doses of diazepam in schizophrenics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3930095/),%,91 to 102,15854,DB00231,Temazepam
,3930095,Analytical recovery,"Analytical recovery of each drug added to the serum varied from 91 to 102% for oxazepam and temazepam, from 82 to 99% for nordiazepam and diazepam.","Liquid-chromatographic assay of diazepam and its major metabolites in serum, and application to pharmacokinetic study of high doses of diazepam in schizophrenics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3930095/),%,82 to 99,15855,DB00231,Temazepam
,2574013,distribution half-life,The decline in plasma concentration was biexponential with a distribution half-life of 1.24 hours.,Premedication with temazepam in minor surgery. The relationship between plasma concentration and clinical effect after a dose of 40 mg. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2574013/),h,1.24,25751,DB00231,Temazepam
,6142905,volume of distribution,"Mean kinetic variables were: volume of distribution, 1.45 liter/kg; elimination half-life, 8.6 hours; total clearance, 2.33 ml/min/kg.",Is temazepam an accumulating hypnotic? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142905/),[l] / [kg],1.45,42562,DB00231,Temazepam
,6142905,elimination half-life,"Mean kinetic variables were: volume of distribution, 1.45 liter/kg; elimination half-life, 8.6 hours; total clearance, 2.33 ml/min/kg.",Is temazepam an accumulating hypnotic? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142905/),h,8.6,42563,DB00231,Temazepam
,6142905,total clearance,"Mean kinetic variables were: volume of distribution, 1.45 liter/kg; elimination half-life, 8.6 hours; total clearance, 2.33 ml/min/kg.",Is temazepam an accumulating hypnotic? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142905/),[ml] / [kg·min],2.33,42564,DB00231,Temazepam
,6142905,accumulation ratio,"Based on the area under the serum concentration curve after the last dose compared with that after the first dose, the mean accumulation ratio was 1.32, which was significantly greater than unity.",Is temazepam an accumulating hypnotic? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142905/),,1.32,42565,DB00231,Temazepam
,6142905,washout half-life,Postdosage washout half-life averaged 10.2 hours.,Is temazepam an accumulating hypnotic? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142905/),h,10.2,42566,DB00231,Temazepam
,41539,half lives,"Values were obtained for excretion pattern (0-infinity), half lives (1.95, 0.5, 10.0 and 1.9 h), amounts in all compartments, and for steady-state conditions.",Pharmacokinetics and metabolism of temazepam in man and several animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/41539/),h,1.95,44492,DB00231,Temazepam
,41539,half lives,"Values were obtained for excretion pattern (0-infinity), half lives (1.95, 0.5, 10.0 and 1.9 h), amounts in all compartments, and for steady-state conditions.",Pharmacokinetics and metabolism of temazepam in man and several animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/41539/),h,0.5,44493,DB00231,Temazepam
,41539,half lives,"Values were obtained for excretion pattern (0-infinity), half lives (1.95, 0.5, 10.0 and 1.9 h), amounts in all compartments, and for steady-state conditions.",Pharmacokinetics and metabolism of temazepam in man and several animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/41539/),h,10.0,44494,DB00231,Temazepam
,41539,half lives,"Values were obtained for excretion pattern (0-infinity), half lives (1.95, 0.5, 10.0 and 1.9 h), amounts in all compartments, and for steady-state conditions.",Pharmacokinetics and metabolism of temazepam in man and several animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/41539/),h,1.9,44495,DB00231,Temazepam
,6143815,peak plasma concentration,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),[ng] / [ml],560,47687,DB00231,Temazepam
,6143815,peak plasma concentration,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),[ng] / [ml],498,47688,DB00231,Temazepam
,6143815,time of peak concentration,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),h,2.0,47689,DB00231,Temazepam
,6143815,time of peak concentration,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),h,2.1,47690,DB00231,Temazepam
,6143815,volume of distribution,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),[l] / [kg],1.30,47691,DB00231,Temazepam
,6143815,volume of distribution,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),[l] / [kg],1.39,47692,DB00231,Temazepam
,6143815,elimination half-life,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),h,9.9,47693,DB00231,Temazepam
,6143815,elimination half-life,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),h,11.4,47694,DB00231,Temazepam
,6143815,total clearance,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),[ml] / [kg·min],1.59,47695,DB00231,Temazepam
,6143815,total clearance,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),[ml] / [kg·min],1.60,47696,DB00231,Temazepam
,6143815,free fraction,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),%,4.1,47697,DB00231,Temazepam
,6143815,free fraction,"Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound.",Noninteraction of temazepam and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143815/),%,3.8,47698,DB00231,Temazepam
,32219697,time of maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,1.04,48787,DB00231,Temazepam
,32219697,time of maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,133.14,48788,DB00231,Temazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],87.37,48789,DB00231,Temazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,129.07,48790,DB00231,Temazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,133.14,48791,DB00231,Temazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],3.80,48792,DB00231,Temazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,100.29,48793,DB00231,Temazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],1.62,48794,DB00231,Temazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,44.43,48795,DB00231,Temazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,66.86,48796,DB00231,Temazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],1.10,48797,DB00231,Temazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,129.07,48798,DB00231,Temazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,382.86,48799,DB00231,Temazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,44.43,48800,DB00231,Temazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],2.08,48801,DB00231,Temazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,130.53,48802,DB00231,Temazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,66.86,48803,DB00231,Temazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],1.10,48804,DB00231,Temazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,240.66,48805,DB00231,Temazepam
,1424412,apparent duration of effects,The apparent duration of effects ranged from 3 to 9 hours in individual subjects.,Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424412/),h,3 to 9,55804,DB00231,Temazepam
,6142469,half-life,"The final metabolite, desalkylflurazepam, appears slowly, but has a long half-life ranging from 40 to 150 h.",Pharmacokinetics of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142469/),h,40 to 150,57886,DB00231,Temazepam
,6142469,half-life,Temazepam is a slowly absorbed drug and has an intermediate half-life in the range of 10-20 h.,Pharmacokinetics of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142469/),h,10-20,57887,DB00231,Temazepam
,6142469,half-life,"Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating.",Pharmacokinetics of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142469/),h,1.5-5,57888,DB00231,Temazepam
,31010782,peak diazepam concentration (Cmax),The mean peak diazepam concentration (Cmax) of 31.0 ng/mL was detected at a mean time (Tmax) of 3.1 hours after suppository placement.,Vaginal Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic Profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010782/),[ng] / [ml],31.0,60194,DB00231,Temazepam
,31010782,time (Tmax),The mean peak diazepam concentration (Cmax) of 31.0 ng/mL was detected at a mean time (Tmax) of 3.1 hours after suppository placement.,Vaginal Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic Profile. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010782/),h,3.1,60195,DB00231,Temazepam
,31010782,bioavailability,"The bioavailability was found to be 70.5%, and the mean terminal elimination half-life was 82 hours.",Vaginal Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic Profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010782/),%,70.5,60196,DB00231,Temazepam
,31010782,terminal elimination half-life,"The bioavailability was found to be 70.5%, and the mean terminal elimination half-life was 82 hours.",Vaginal Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic Profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010782/),h,82,60197,DB00231,Temazepam
,6127087,protein binding,The protein binding of camazepam in dog plasma was studied by using the equilibrium dialysis method and found to vary from 88.5 to 76.7% when the total drug concentration increased from 8 ng/ml to 8 micrograms/ml.,Pharmacokinetics of intravenous camazepam in dogs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127087/),%,88.5 to 76.7,67003,DB00231,Temazepam
,6127087,half-life of the terminal elimination phase,"The half-life of the terminal elimination phase ranged from 6.4 to 10.5 h, a finding which might suggest that camazepam could exhibit long-lasting effects.",Pharmacokinetics of intravenous camazepam in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127087/),h,6.4 to 10.5,67004,DB00231,Temazepam
,1783647,limit of detection,The limit of detection is 15.5 ng/ml and the limit of quantitation is 46.5 ng/ml.,Determination of temazepam and temazepam glucuronide by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783647/),[ng] / [ml],15.5,72358,DB00231,Temazepam
,1783647,limit of quantitation,The limit of detection is 15.5 ng/ml and the limit of quantitation is 46.5 ng/ml.,Determination of temazepam and temazepam glucuronide by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783647/),ng,46,72359,DB00231,Temazepam
,2390424,elimination half-life,"Values of elimination half-life ranged from 13.1 to 44.7 h, systemic clearance from 1.02 to 1.63 l h-1 and volume of distribution from 1390 to 3940 l and these were similar to those obtained with bolus administration.",Pharmacokinetics of propofol when given by intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),h,13.1 to 44.7,76761,DB00231,Temazepam
,2390424,systemic clearance,"Values of elimination half-life ranged from 13.1 to 44.7 h, systemic clearance from 1.02 to 1.63 l h-1 and volume of distribution from 1390 to 3940 l and these were similar to those obtained with bolus administration.",Pharmacokinetics of propofol when given by intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),[l] / [h],1.02 to 1.63,76762,DB00231,Temazepam
,2390424,volume of distribution,"Values of elimination half-life ranged from 13.1 to 44.7 h, systemic clearance from 1.02 to 1.63 l h-1 and volume of distribution from 1390 to 3940 l and these were similar to those obtained with bolus administration.",Pharmacokinetics of propofol when given by intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),l,1390 to 3940,76763,DB00231,Temazepam
,2390424,o,"The large volume of distribution is consistent with the high octanol/blood partition coefficient, which was found to be 72.0.",Pharmacokinetics of propofol when given by intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),,72.0,76764,DB00231,Temazepam
shorter,22929751,elimination half-life,"In theory, accumulation does not occur with once-daily dosage of benzodiazepines that have an elimination half-life markedly shorter than 24 h, such as oxazepam, temazepam, and lorazepam.",[Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22929751/),h,24,77548,DB00231,Temazepam
,34115414,plasma clearance,"The mean plasma clearance of DIA was 5.9 ml/min/kg, and the plasma elimination half-life in the terminal phase was 19.9 h.",Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34115414/),[ml] / [kg·min],5.9,83712,DB00231,Temazepam
,34115414,plasma elimination half-life in the terminal phase,"The mean plasma clearance of DIA was 5.9 ml/min/kg, and the plasma elimination half-life in the terminal phase was 19.9 h.",Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34115414/),h,19.9,83713,DB00231,Temazepam
,34115414,detection time,"The detection time according to the European Horserace Scientific Liaison Committee (EHSLC), that is the time for which observed DIA plasma concentrations of all investigated horses were below the IPC was 10 days.",Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34115414/),d,10,83714,DB00231,Temazepam
,2874007,half-life,"As loprazolam has a half-life of 7 to 8 hours in healthy adults it may have advantages over longer-acting hypnotics, particularly when residual sedative effects on the day after ingestion are undesirable, although at doses greater than 1 mg residual sedation may occur.",Loprazolam. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in insomnia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874007/),h,7 to 8,84334,DB00231,Temazepam
,33041783,IC50,"The IC50 values of imperatorin to nordazepam and temazepam were 1.54 μM and 1.80 μM, respectively.",Inhibitory Effect of Imperatorin on the Pharmacokinetics of Diazepam In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041783/),μM,1.54,87586,DB00231,Temazepam
,33041783,IC50,"The IC50 values of imperatorin to nordazepam and temazepam were 1.54 μM and 1.80 μM, respectively.",Inhibitory Effect of Imperatorin on the Pharmacokinetics of Diazepam In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041783/),μM,1.80,87587,DB00231,Temazepam
,33041783,inhibitory constant,"The inhibitory constant values for temazepam and nordazepam were 1.24 μM and 1.29 μM, respectively.",Inhibitory Effect of Imperatorin on the Pharmacokinetics of Diazepam In Vitro and In Vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041783/),μM,1.24,87588,DB00231,Temazepam
,33041783,inhibitory constant,"The inhibitory constant values for temazepam and nordazepam were 1.24 μM and 1.29 μM, respectively.",Inhibitory Effect of Imperatorin on the Pharmacokinetics of Diazepam In Vitro and In Vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041783/),μM,1.29,87589,DB00231,Temazepam
,6138889,percentage recoveries,"The percentage recoveries of nitrazepam and temazepam were 79% and 85%, respectively.",Determination of nitrazepam and temazepam in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138889/),%,79,109497,DB00231,Temazepam
,6138889,percentage recoveries,"The percentage recoveries of nitrazepam and temazepam were 79% and 85%, respectively.",Determination of nitrazepam and temazepam in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138889/),%,85,109498,DB00231,Temazepam
,1389938,total AUC,The mean total AUC of the 5 mu preparation was significantly reduced by gargling (3153 ng ml-1 h to 1066 ng ml-1 h) (F = 0.32).,The influence of particle size on the bioavailability of inhaled temazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389938/),[h·ng] / [ml],3153,114092,DB00231,Temazepam
,1389938,total AUC,The mean total AUC of the 5 mu preparation was significantly reduced by gargling (3153 ng ml-1 h to 1066 ng ml-1 h) (F = 0.32).,The influence of particle size on the bioavailability of inhaled temazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389938/),[h·ng] / [ml],1066,114093,DB00231,Temazepam
,1389938,AUC,4. In contrast gargling had no significant effect on the mean AUC associated with the smaller diameter particle preparation (630 ng ml-1 h) vs 397 ng ml-1 h (F = 0.74).,The influence of particle size on the bioavailability of inhaled temazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389938/),[h·ng] / [ml],630,114094,DB00231,Temazepam
,1389938,AUC,4. In contrast gargling had no significant effect on the mean AUC associated with the smaller diameter particle preparation (630 ng ml-1 h) vs 397 ng ml-1 h (F = 0.74).,The influence of particle size on the bioavailability of inhaled temazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389938/),[h·ng] / [ml],397,114095,DB00231,Temazepam
,8166961,Residue concentrations,"Residue concentrations were reduced from 9.7 and 243 micrograms in consumed guinea pig liver to 3.75 and 455 ng/g in rat liver for parent drug and oxazepam, the lowest and highest residues found, respectively.",Bioavailability of residues of diazepam and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166961/),μg,9.7,117994,DB00231,Temazepam
,8166961,Residue concentrations,"Residue concentrations were reduced from 9.7 and 243 micrograms in consumed guinea pig liver to 3.75 and 455 ng/g in rat liver for parent drug and oxazepam, the lowest and highest residues found, respectively.",Bioavailability of residues of diazepam and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166961/),μg,243,117995,DB00231,Temazepam
,8166961,Residue concentrations,"Residue concentrations were reduced from 9.7 and 243 micrograms in consumed guinea pig liver to 3.75 and 455 ng/g in rat liver for parent drug and oxazepam, the lowest and highest residues found, respectively.",Bioavailability of residues of diazepam and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166961/),[ng] / [g],3.75,117996,DB00231,Temazepam
,8166961,Residue concentrations,"Residue concentrations were reduced from 9.7 and 243 micrograms in consumed guinea pig liver to 3.75 and 455 ng/g in rat liver for parent drug and oxazepam, the lowest and highest residues found, respectively.",Bioavailability of residues of diazepam and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166961/),[ng] / [g],455,117997,DB00231,Temazepam
,29682729,Vd,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),ml,608,124751,DB00231,Temazepam
,29682729,CL,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),[ml] / [min],22.1,124752,DB00231,Temazepam
,29682729,CL,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),min,13.7,124753,DB00231,Temazepam
,29682729,t1/2α (,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),[ml] / [min],22.1,124754,DB00231,Temazepam
,29682729,t1/2α (,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),min,13.7,124755,DB00231,Temazepam
,29682729,distribution half-life),"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),[ml] / [min],22.1,124756,DB00231,Temazepam
,29682729,distribution half-life),"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),min,13.7,124757,DB00231,Temazepam
,29682729,t1/2β (terminal half-life),"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),min,76.8,124758,DB00231,Temazepam
,29682729,minimal plasma diazepam concentration,The minimal plasma diazepam concentration associated with threshold elevations was estimated at approximately 70 ng/mL.,Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),[ng] / [ml],70,124759,DB00231,Temazepam
,20375123,peak serum concentrations,"For temazepam and oxazepam, peak serum concentrations were 8.5 and 1.3 mg/L, respectively.",Toxicokinetics of a dipyridamole (Persantin) intoxication: case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20375123/),[mg] / [l],8.5,131399,DB00231,Temazepam
,20375123,peak serum concentrations,"For temazepam and oxazepam, peak serum concentrations were 8.5 and 1.3 mg/L, respectively.",Toxicokinetics of a dipyridamole (Persantin) intoxication: case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20375123/),[mg] / [l],1.3,131400,DB00231,Temazepam
,2882760,uptake ratios,"Highest uptake ratios relative to free (unbound) drug in plasma were in adrenal (56-135), liver (35-116) and kidney (19-50).","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,56-135,142641,DB00231,Temazepam
,2882760,uptake ratios,"Highest uptake ratios relative to free (unbound) drug in plasma were in adrenal (56-135), liver (35-116) and kidney (19-50).","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,35-116,142642,DB00231,Temazepam
,2882760,uptake ratios,"Highest uptake ratios relative to free (unbound) drug in plasma were in adrenal (56-135), liver (35-116) and kidney (19-50).","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,19-50,142643,DB00231,Temazepam
,2882760,Free fraction,"Free fraction in plasma varied from 0.13 for desmethyldiazepam to 0.30 for triazolam, and was unrelated to age.","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,0.13,142644,DB00231,Temazepam
,2882760,Free fraction,"Free fraction in plasma varied from 0.13 for desmethyldiazepam to 0.30 for triazolam, and was unrelated to age.","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,0.30,142645,DB00231,Temazepam
,2867675,elimination half-life,"Temazepam volume of distribution was smaller in cirrhotics compared to controls, and elimination half-life shorter (10.6 versus 14.6 h).",Temazepam clearance unaltered in cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867675/),h,10.6,145142,DB00231,Temazepam
,2867675,elimination half-life,"Temazepam volume of distribution was smaller in cirrhotics compared to controls, and elimination half-life shorter (10.6 versus 14.6 h).",Temazepam clearance unaltered in cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867675/),h,14.6,145143,DB00231,Temazepam
,2867675,clearance,"There were no significant differences between cirrhotics and controls in clearance of total temazepam (1.03 versus 1.03 ml/min/kg), clearance of unbound temazepam (27 versus 31 ml/min/kg), or free fraction in serum (3.9 versus 3.5% unbound).",Temazepam clearance unaltered in cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867675/),[ml] / [kg·min],1.03,145144,DB00231,Temazepam
,2867675,clearance of unbound temazepam,"There were no significant differences between cirrhotics and controls in clearance of total temazepam (1.03 versus 1.03 ml/min/kg), clearance of unbound temazepam (27 versus 31 ml/min/kg), or free fraction in serum (3.9 versus 3.5% unbound).",Temazepam clearance unaltered in cirrhosis. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867675/),[ml] / [kg·min],27,145145,DB00231,Temazepam
,2867675,clearance of unbound temazepam,"There were no significant differences between cirrhotics and controls in clearance of total temazepam (1.03 versus 1.03 ml/min/kg), clearance of unbound temazepam (27 versus 31 ml/min/kg), or free fraction in serum (3.9 versus 3.5% unbound).",Temazepam clearance unaltered in cirrhosis. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867675/),[ml] / [kg·min],31,145146,DB00231,Temazepam
,2867675,free fraction in serum,"There were no significant differences between cirrhotics and controls in clearance of total temazepam (1.03 versus 1.03 ml/min/kg), clearance of unbound temazepam (27 versus 31 ml/min/kg), or free fraction in serum (3.9 versus 3.5% unbound).",Temazepam clearance unaltered in cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867675/),%,3.9,145147,DB00231,Temazepam
,2867675,free fraction in serum,"There were no significant differences between cirrhotics and controls in clearance of total temazepam (1.03 versus 1.03 ml/min/kg), clearance of unbound temazepam (27 versus 31 ml/min/kg), or free fraction in serum (3.9 versus 3.5% unbound).",Temazepam clearance unaltered in cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867675/),%,3.5,145148,DB00231,Temazepam
,6132989,half-life,"Elimination of the radioactive dose was rapid during 0-8 hr, with a half-life of approximately 1 hr.",Biliary excretion of [14C]temazepam and its metabolites in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132989/),h,1,155200,DB00231,Temazepam
,2105100,milk: plasma ratios,"Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found in the maternal plasma and milk with mean milk: plasma ratios of 0.2, 0.13, 0.14 and 0.10 respectively.",Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105100/),,0.2,165364,DB00231,Temazepam
,2105100,milk: plasma ratios,"Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found in the maternal plasma and milk with mean milk: plasma ratios of 0.2, 0.13, 0.14 and 0.10 respectively.",Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105100/),,0.13,165365,DB00231,Temazepam
,2105100,milk: plasma ratios,"Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found in the maternal plasma and milk with mean milk: plasma ratios of 0.2, 0.13, 0.14 and 0.10 respectively.",Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105100/),,0.14,165366,DB00231,Temazepam
,2105100,milk: plasma ratios,"Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found in the maternal plasma and milk with mean milk: plasma ratios of 0.2, 0.13, 0.14 and 0.10 respectively.",Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105100/),,0.10,165367,DB00231,Temazepam
,2891534,absorption half-life,"The absorption of temazepam was slower after evening administration; the absorption half-life and time to reach maximal plasma concentration being 0.53 h and 1.67 h respectively, compared to 0.38 h and 1.02 h following morning administration.",Pharmacokinetics of temazepam after day-time and night-time oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891534/),h,0.53,168727,DB00231,Temazepam
,2891534,absorption half-life,"The absorption of temazepam was slower after evening administration; the absorption half-life and time to reach maximal plasma concentration being 0.53 h and 1.67 h respectively, compared to 0.38 h and 1.02 h following morning administration.",Pharmacokinetics of temazepam after day-time and night-time oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891534/),h,0.38,168728,DB00231,Temazepam
,2891534,time to reach maximal plasma concentration,"The absorption of temazepam was slower after evening administration; the absorption half-life and time to reach maximal plasma concentration being 0.53 h and 1.67 h respectively, compared to 0.38 h and 1.02 h following morning administration.",Pharmacokinetics of temazepam after day-time and night-time oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891534/),h,1.67,168729,DB00231,Temazepam
,2891534,time to reach maximal plasma concentration,"The absorption of temazepam was slower after evening administration; the absorption half-life and time to reach maximal plasma concentration being 0.53 h and 1.67 h respectively, compared to 0.38 h and 1.02 h following morning administration.",Pharmacokinetics of temazepam after day-time and night-time oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891534/),h,1.02,168730,DB00231,Temazepam
,2891534,peak plasma temazepam concentration,"Considering distribution characteristics, evening administration produced a lower peak plasma temazepam concentration (362 ng/ml) compared with a day-time level of 510 ng/ml.",Pharmacokinetics of temazepam after day-time and night-time oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891534/),[ng] / [ml],362,168731,DB00231,Temazepam
,2891534,peak plasma temazepam concentration,"Considering distribution characteristics, evening administration produced a lower peak plasma temazepam concentration (362 ng/ml) compared with a day-time level of 510 ng/ml.",Pharmacokinetics of temazepam after day-time and night-time oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891534/),[ng] / [ml],510,168732,DB00231,Temazepam
,2891534,Distribution half-life,Distribution half-life after night-time administration was increased compared with day-time administration (1.76 h vs 1.03 h).,Pharmacokinetics of temazepam after day-time and night-time oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891534/),h,1.76,168733,DB00231,Temazepam
,2891534,Distribution half-life,Distribution half-life after night-time administration was increased compared with day-time administration (1.76 h vs 1.03 h).,Pharmacokinetics of temazepam after day-time and night-time oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891534/),h,1.03,168734,DB00231,Temazepam
,32422903,entrapment efficiency,"The optimum formulation (NLC-1) consisted of; Compritol® 888 ATO (75 mg), oleic acid (25 mg), and Poloxamer® 407 (0.3 g), with an entrapment efficiency of 75.2 ± 0.1%.",Nanostructured Lipid Carriers to Mediate Brain Delivery of Temazepam: Design and In Vivo Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32422903/),%,75.2,173379,DB00231,Temazepam
,32422903,size,"The average size, zeta potential, and polydispersity index were determined to be 306.6 ± 49.6 nm, -10.2 ± 0.3 mV, and 0.09 ± 0.10, respectively.",Nanostructured Lipid Carriers to Mediate Brain Delivery of Temazepam: Design and In Vivo Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32422903/),nm,306.6,173380,DB00231,Temazepam
,32422903,zeta potential,"The average size, zeta potential, and polydispersity index were determined to be 306.6 ± 49.6 nm, -10.2 ± 0.3 mV, and 0.09 ± 0.10, respectively.",Nanostructured Lipid Carriers to Mediate Brain Delivery of Temazepam: Design and In Vivo Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32422903/),mv,-,173381,DB00231,Temazepam
,32422903,polydispersity index,"The average size, zeta potential, and polydispersity index were determined to be 306.6 ± 49.6 nm, -10.2 ± 0.3 mV, and 0.09 ± 0.10, respectively.",Nanostructured Lipid Carriers to Mediate Brain Delivery of Temazepam: Design and In Vivo Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32422903/),mv,10.2,173382,DB00231,Temazepam
,32422903,polydispersity index,"The average size, zeta potential, and polydispersity index were determined to be 306.6 ± 49.6 nm, -10.2 ± 0.3 mV, and 0.09 ± 0.10, respectively.",Nanostructured Lipid Carriers to Mediate Brain Delivery of Temazepam: Design and In Vivo Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32422903/),,0.09,173383,DB00231,Temazepam
,32422903,relative bioavailability,"Pharmacokinetic data revealed a significant increase in the relative bioavailability of 99mTc-temazepam NLC-1 formulation (292.7%), compared to that of oral 99mTc-temazepam suspension.",Nanostructured Lipid Carriers to Mediate Brain Delivery of Temazepam: Design and In Vivo Study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32422903/),%,292.7,173384,DB00231,Temazepam
,2874974,half-life,"Minimal impairment of psychomotor skills and mental acuity occurs in the morning after a bedtime dose of zopiclone, which has a short half-life of about 5 hours and no long acting metabolites.",Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874974/),h,5,173477,DB00231,Temazepam
,11339294,flow-rate,"The compounds were extracted using C18 Sep-Pak Vac 3cc (500 mg) cartridges and separated using isocratic mobile phase of methanol, acetonitrile and water (pH 3.2) (10:40:50) at a flow-rate of 0.5 ml/min in a period of 12 min, and UV detection ranging between 240 and 280 nm.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),[ml] / [min],0.5,176397,DB00231,Temazepam
,11339294,limits of detection,"The limits of detection for all analytes ranged between 20 and 50 ng/ml, while limits of quantitation were 100 ng/ml.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),[ng] / [ml],20 and 50,176398,DB00231,Temazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,79.1,176399,DB00231,Temazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,83.5,176400,DB00231,Temazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,83.9,176401,DB00231,Temazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,71.3,176402,DB00231,Temazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,77.7,176403,DB00231,Temazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,79.4,176404,DB00231,Temazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,83.1,176405,DB00231,Temazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,73.6,176406,DB00231,Temazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,74.3,176407,DB00231,Temazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,77.6,176408,DB00231,Temazepam
,7588138,volume of distribution,"Peak plasma temazepam concentrations were achieved rapidly (within 1 h post drug administration) and the estimated volume of distribution (mean: 1.13 1/kg), total clearance (mean: 1.6 ml/min/kg) and terminal elimination half-life (mean: 8 hours) were comparable to previously reported values in healthy subjects.",Pharmacokinetics of temazepam in male surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588138/),[1] / [kg],1.13,181288,DB00231,Temazepam
,7588138,total clearance,"Peak plasma temazepam concentrations were achieved rapidly (within 1 h post drug administration) and the estimated volume of distribution (mean: 1.13 1/kg), total clearance (mean: 1.6 ml/min/kg) and terminal elimination half-life (mean: 8 hours) were comparable to previously reported values in healthy subjects.",Pharmacokinetics of temazepam in male surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588138/),[ml] / [kg·min],1.6,181289,DB00231,Temazepam
,7588138,terminal elimination half-life,"Peak plasma temazepam concentrations were achieved rapidly (within 1 h post drug administration) and the estimated volume of distribution (mean: 1.13 1/kg), total clearance (mean: 1.6 ml/min/kg) and terminal elimination half-life (mean: 8 hours) were comparable to previously reported values in healthy subjects.",Pharmacokinetics of temazepam in male surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588138/),h,8,181290,DB00231,Temazepam
,2860283,Peak concentrations,"Peak concentrations of plasma temazepam were reached at about one hour, and they were higher after the capsule than after the tablet (mean values 750 vs. 587 ng/ml), while the computed AUCs and elimination half-lives (6-22 hours) proved to be similar after either formulation.",Acute pharmacokinetic and pharmacodynamic comparison of two different formulations of temazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2860283/),[ng] / [ml],750,184599,DB00231,Temazepam
,2860283,Peak concentrations,"Peak concentrations of plasma temazepam were reached at about one hour, and they were higher after the capsule than after the tablet (mean values 750 vs. 587 ng/ml), while the computed AUCs and elimination half-lives (6-22 hours) proved to be similar after either formulation.",Acute pharmacokinetic and pharmacodynamic comparison of two different formulations of temazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2860283/),[ng] / [ml],587,184600,DB00231,Temazepam
,2860283,AUCs,"Peak concentrations of plasma temazepam were reached at about one hour, and they were higher after the capsule than after the tablet (mean values 750 vs. 587 ng/ml), while the computed AUCs and elimination half-lives (6-22 hours) proved to be similar after either formulation.",Acute pharmacokinetic and pharmacodynamic comparison of two different formulations of temazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2860283/),h,6-22,184601,DB00231,Temazepam
,2860283,elimination half-lives,"Peak concentrations of plasma temazepam were reached at about one hour, and they were higher after the capsule than after the tablet (mean values 750 vs. 587 ng/ml), while the computed AUCs and elimination half-lives (6-22 hours) proved to be similar after either formulation.",Acute pharmacokinetic and pharmacodynamic comparison of two different formulations of temazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2860283/),h,6-22,184602,DB00231,Temazepam
,6145683,half-life,"The final metabolite, desalkylflurazepam, appears slowly, but has a long half-life ranging from 40 to 150 h.",Pharmacokinetics of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145683/),h,40 to 150,185030,DB00231,Temazepam
,6145683,half-life,Temazepam is a slowly absorbed drug and has an intermediate half-life in the range of 10-20 h.,Pharmacokinetics of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145683/),h,10-20,185031,DB00231,Temazepam
,6145683,half-life,"Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating.",Pharmacokinetics of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145683/),h,1.5-5,185032,DB00231,Temazepam
,8826537,Frel,"Serum levels of temazepam indicate an instantaneous and complete release from the micro-enema (Frel = 0.94 +/- 0.21, Cmax 205 +/- 36.9 micrograms/l, tmax 0.49 +/- 0.31 hour) and a slower but complete release of temazepam from the suppository (Frel = 1.10 +/- 0.25, Cmax 202 +/- 41.3 micrograms/l, tmax 1.48 +/- 0.41 hour).",Pharmacokinetic aspects of rectal formulations of temazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826537/),,0.94,187295,DB00231,Temazepam
,8826537,Cmax,"Serum levels of temazepam indicate an instantaneous and complete release from the micro-enema (Frel = 0.94 +/- 0.21, Cmax 205 +/- 36.9 micrograms/l, tmax 0.49 +/- 0.31 hour) and a slower but complete release of temazepam from the suppository (Frel = 1.10 +/- 0.25, Cmax 202 +/- 41.3 micrograms/l, tmax 1.48 +/- 0.41 hour).",Pharmacokinetic aspects of rectal formulations of temazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826537/),[μg] / [l],205,187296,DB00231,Temazepam
,8826537,tmax,"Serum levels of temazepam indicate an instantaneous and complete release from the micro-enema (Frel = 0.94 +/- 0.21, Cmax 205 +/- 36.9 micrograms/l, tmax 0.49 +/- 0.31 hour) and a slower but complete release of temazepam from the suppository (Frel = 1.10 +/- 0.25, Cmax 202 +/- 41.3 micrograms/l, tmax 1.48 +/- 0.41 hour).",Pharmacokinetic aspects of rectal formulations of temazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826537/),h,0.49,187297,DB00231,Temazepam
,8826537,Frel,"Serum levels of temazepam indicate an instantaneous and complete release from the micro-enema (Frel = 0.94 +/- 0.21, Cmax 205 +/- 36.9 micrograms/l, tmax 0.49 +/- 0.31 hour) and a slower but complete release of temazepam from the suppository (Frel = 1.10 +/- 0.25, Cmax 202 +/- 41.3 micrograms/l, tmax 1.48 +/- 0.41 hour).",Pharmacokinetic aspects of rectal formulations of temazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826537/),,1.10,187298,DB00231,Temazepam
,8826537,Cmax,"Serum levels of temazepam indicate an instantaneous and complete release from the micro-enema (Frel = 0.94 +/- 0.21, Cmax 205 +/- 36.9 micrograms/l, tmax 0.49 +/- 0.31 hour) and a slower but complete release of temazepam from the suppository (Frel = 1.10 +/- 0.25, Cmax 202 +/- 41.3 micrograms/l, tmax 1.48 +/- 0.41 hour).",Pharmacokinetic aspects of rectal formulations of temazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826537/),[μg] / [l],202,187299,DB00231,Temazepam
,8826537,tmax,"Serum levels of temazepam indicate an instantaneous and complete release from the micro-enema (Frel = 0.94 +/- 0.21, Cmax 205 +/- 36.9 micrograms/l, tmax 0.49 +/- 0.31 hour) and a slower but complete release of temazepam from the suppository (Frel = 1.10 +/- 0.25, Cmax 202 +/- 41.3 micrograms/l, tmax 1.48 +/- 0.41 hour).",Pharmacokinetic aspects of rectal formulations of temazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826537/),h,1.48,187300,DB00231,Temazepam
,8826537,Frel,"A high interindividual variation in absorption profiles was observed after rectal administration of the liquid-filled capsule (Frel 0.72 +/- 0.36, Cmax 182 +/- 122 micrograms/l, tmax 4.08 +/- 4.28 hour), which makes it less suitable for rectal use.",Pharmacokinetic aspects of rectal formulations of temazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826537/),,0.72,187301,DB00231,Temazepam
,8826537,Cmax,"A high interindividual variation in absorption profiles was observed after rectal administration of the liquid-filled capsule (Frel 0.72 +/- 0.36, Cmax 182 +/- 122 micrograms/l, tmax 4.08 +/- 4.28 hour), which makes it less suitable for rectal use.",Pharmacokinetic aspects of rectal formulations of temazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826537/),[μg] / [l],182,187302,DB00231,Temazepam
,8826537,tmax,"A high interindividual variation in absorption profiles was observed after rectal administration of the liquid-filled capsule (Frel 0.72 +/- 0.36, Cmax 182 +/- 122 micrograms/l, tmax 4.08 +/- 4.28 hour), which makes it less suitable for rectal use.",Pharmacokinetic aspects of rectal formulations of temazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826537/),h,4.08,187303,DB00231,Temazepam
,11470209,analytical run time,The analytical run time was 5 min.,The simultaneous determination of diazepam and its three metabolites in dog plasma by high-performance liquid chromatography with mass spectroscopy detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11470209/),min,5,194420,DB00231,Temazepam
,2858279,terminal t1/2,"In the remaining subjects, temazepam elimination was biphasic, with the terminal t1/2 ranging from 11 to 77 hours.",Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858279/),h,11 to 77,208543,DB00231,Temazepam
,2858279,percent free,The percent free temazepam in plasma from dialysis subjects ranged from 4.4% to 8.8% (mean = 5.9%).,Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858279/),,4,208544,DB00231,Temazepam
,2858279,percent free,The percent free temazepam in plasma from dialysis subjects ranged from 4.4% to 8.8% (mean = 5.9%).,Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858279/),,8.,208545,DB00231,Temazepam
,2858279,percent free,The percent free temazepam in plasma from dialysis subjects ranged from 4.4% to 8.8% (mean = 5.9%).,Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858279/),,5,208546,DB00231,Temazepam
,1425620,tmax,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,1.9,210774,DB00231,Temazepam
,1425620,absolute bioavailability,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),%,60,210775,DB00231,Temazepam
,1425620,terminal elimination half-life,Its terminal elimination half-life is 3.5 h and it is extensively hepatically metabolized.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,3.5,210776,DB00231,Temazepam
,1425620,Plasma clearance,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [h·kg],0.38,210777,DB00231,Temazepam
,1425620,volume of distribution,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [kg],1.8,210778,DB00231,Temazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,4.9,216455,DB00231,Temazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,9.2,216456,DB00231,Temazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,1.0,216457,DB00231,Temazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,6.2,216458,DB00231,Temazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,2.4,216459,DB00231,Temazepam
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],2.37,216460,DB00231,Temazepam
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],0.935,216461,DB00231,Temazepam
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],27.9,216462,DB00231,Temazepam
,21692812,C(MAX),"The C(MAX) was 44.7 and 305.2 ng/mL for oxazepam and nordiazepam, respectively, after diazepam administration.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[ng] / [ml],44.7,216463,DB00231,Temazepam
,21692812,C(MAX),"The C(MAX) was 44.7 and 305.2 ng/mL for oxazepam and nordiazepam, respectively, after diazepam administration.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[ng] / [ml],305.2,216464,DB00231,Temazepam
,2207300,peak plasma level (Cmax),"Mean kinetic variables for temazepam in plasma were: peak plasma level (Cmax), 873 ng ml-1; time of peak, 1.36 h after dosage; volume of distribution, 0.961 kg-1; elimination half-life 9.9 h; clearance, 1.16 ml min-1 kg-1.",Oxidative versus conjugative biotransformation of temazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207300/),[ng] / [ml],873,225970,DB00231,Temazepam
,2207300,time of peak,"Mean kinetic variables for temazepam in plasma were: peak plasma level (Cmax), 873 ng ml-1; time of peak, 1.36 h after dosage; volume of distribution, 0.961 kg-1; elimination half-life 9.9 h; clearance, 1.16 ml min-1 kg-1.",Oxidative versus conjugative biotransformation of temazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207300/),h,1.36,225971,DB00231,Temazepam
,2207300,volume of distribution,"Mean kinetic variables for temazepam in plasma were: peak plasma level (Cmax), 873 ng ml-1; time of peak, 1.36 h after dosage; volume of distribution, 0.961 kg-1; elimination half-life 9.9 h; clearance, 1.16 ml min-1 kg-1.",Oxidative versus conjugative biotransformation of temazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207300/),1/[kg],0.961,225972,DB00231,Temazepam
,2207300,elimination half-life,"Mean kinetic variables for temazepam in plasma were: peak plasma level (Cmax), 873 ng ml-1; time of peak, 1.36 h after dosage; volume of distribution, 0.961 kg-1; elimination half-life 9.9 h; clearance, 1.16 ml min-1 kg-1.",Oxidative versus conjugative biotransformation of temazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207300/),h,9.9,225973,DB00231,Temazepam
,2207300,clearance,"Mean kinetic variables for temazepam in plasma were: peak plasma level (Cmax), 873 ng ml-1; time of peak, 1.36 h after dosage; volume of distribution, 0.961 kg-1; elimination half-life 9.9 h; clearance, 1.16 ml min-1 kg-1.",Oxidative versus conjugative biotransformation of temazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207300/),[ml] / [kg·min],1.16,225974,DB00231,Temazepam
,2876901,peak plasma concentration,"The mean peak plasma concentration was 306 ng/ml, with a median time of 0.75 h to peak concentration.",Pharmacokinetics of temazepam in geriatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876901/),[ng] / [ml],306,230024,DB00231,Temazepam
,2876901,time,"The mean peak plasma concentration was 306 ng/ml, with a median time of 0.75 h to peak concentration.",Pharmacokinetics of temazepam in geriatric patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876901/),h,0.75,230025,DB00231,Temazepam
,2876901,t1/2 alpha,"Temazepam was eliminated from plasma in a biexponential manner, with a distribution phase (mean t1/2 alpha = 0.7 h) predominating for 3 h.",Pharmacokinetics of temazepam in geriatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876901/),h,0.7,230026,DB00231,Temazepam
,2876901,elimination half-life,The drug had a mean elimination half-life of 8.7 h.,Pharmacokinetics of temazepam in geriatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876901/),h,8.7,230027,DB00231,Temazepam
,6132931,half-life,Temazepam has a relatively slow rate of absorption and an intermediate half-life in the range of 10 to 20 hours.,Pharmacokinetic properties of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132931/),h,10 to 20,231855,DB00231,Temazepam
,6132931,half-life,"Triazolam has an intermediate rate of absorption; due to its ultrashort half-life (1.5 to 5 hours), triazolam is a non-accumulating hypnotic.",Pharmacokinetic properties of benzodiazepine hypnotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132931/),h,1.5 to 5,231856,DB00231,Temazepam
,1870948,plasma ratio R/S-,The plasma ratio R/S-glucuronide is 1:1 for both oxazepam and temazepam.,Direct high pressure liquid chromatographic analysis and preliminary pharmacokinetics of enantiomers of oxazepam and temazepam with their corresponding glucuronide conjugates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1870948/),,1:,250404,DB00231,Temazepam
,1870948,plasma ratio R/S-,The plasma ratio R/S-glucuronide is 1:1 for both oxazepam and temazepam.,Direct high pressure liquid chromatographic analysis and preliminary pharmacokinetics of enantiomers of oxazepam and temazepam with their corresponding glucuronide conjugates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1870948/),,1,250405,DB00231,Temazepam
,1752914,Cmax,"Although the mean Cmax for TG (616.6 ng/ml) is lower than for TL (707.9 ng/ml) and the median time to reach Cmax (Tmax) is 40 min (TG) vs. 30 min (TL), there is no significant difference between TG and TL either in their absorption constant (Ka) (0.123 vs. 0.138 min-1 respectively) or their distribution (a) (29.5 vs. 32.4 min) and elimination (beta) (6.3 vs. 6.6 h) half-lives (t1/2).",Comparative pharmacokinetics of temazepam Gelthix and liquid-filled soft gelatin capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752914/),[ng] / [ml],616.6,255874,DB00231,Temazepam
,1752914,Cmax,"Although the mean Cmax for TG (616.6 ng/ml) is lower than for TL (707.9 ng/ml) and the median time to reach Cmax (Tmax) is 40 min (TG) vs. 30 min (TL), there is no significant difference between TG and TL either in their absorption constant (Ka) (0.123 vs. 0.138 min-1 respectively) or their distribution (a) (29.5 vs. 32.4 min) and elimination (beta) (6.3 vs. 6.6 h) half-lives (t1/2).",Comparative pharmacokinetics of temazepam Gelthix and liquid-filled soft gelatin capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752914/),[ng] / [ml],707.9,255875,DB00231,Temazepam
,1752914,time to reach Cmax (Tmax),"Although the mean Cmax for TG (616.6 ng/ml) is lower than for TL (707.9 ng/ml) and the median time to reach Cmax (Tmax) is 40 min (TG) vs. 30 min (TL), there is no significant difference between TG and TL either in their absorption constant (Ka) (0.123 vs. 0.138 min-1 respectively) or their distribution (a) (29.5 vs. 32.4 min) and elimination (beta) (6.3 vs. 6.6 h) half-lives (t1/2).",Comparative pharmacokinetics of temazepam Gelthix and liquid-filled soft gelatin capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752914/),min,40,255876,DB00231,Temazepam
,1752914,time to reach Cmax (Tmax),"Although the mean Cmax for TG (616.6 ng/ml) is lower than for TL (707.9 ng/ml) and the median time to reach Cmax (Tmax) is 40 min (TG) vs. 30 min (TL), there is no significant difference between TG and TL either in their absorption constant (Ka) (0.123 vs. 0.138 min-1 respectively) or their distribution (a) (29.5 vs. 32.4 min) and elimination (beta) (6.3 vs. 6.6 h) half-lives (t1/2).",Comparative pharmacokinetics of temazepam Gelthix and liquid-filled soft gelatin capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752914/),min,30,255877,DB00231,Temazepam
,1752914,absorption constant (Ka),"Although the mean Cmax for TG (616.6 ng/ml) is lower than for TL (707.9 ng/ml) and the median time to reach Cmax (Tmax) is 40 min (TG) vs. 30 min (TL), there is no significant difference between TG and TL either in their absorption constant (Ka) (0.123 vs. 0.138 min-1 respectively) or their distribution (a) (29.5 vs. 32.4 min) and elimination (beta) (6.3 vs. 6.6 h) half-lives (t1/2).",Comparative pharmacokinetics of temazepam Gelthix and liquid-filled soft gelatin capsules. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752914/),1/[min],0.123,255878,DB00231,Temazepam
,1752914,absorption constant (Ka),"Although the mean Cmax for TG (616.6 ng/ml) is lower than for TL (707.9 ng/ml) and the median time to reach Cmax (Tmax) is 40 min (TG) vs. 30 min (TL), there is no significant difference between TG and TL either in their absorption constant (Ka) (0.123 vs. 0.138 min-1 respectively) or their distribution (a) (29.5 vs. 32.4 min) and elimination (beta) (6.3 vs. 6.6 h) half-lives (t1/2).",Comparative pharmacokinetics of temazepam Gelthix and liquid-filled soft gelatin capsules. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752914/),1/[min],0.138,255879,DB00231,Temazepam
,1752914,distribution (a),"Although the mean Cmax for TG (616.6 ng/ml) is lower than for TL (707.9 ng/ml) and the median time to reach Cmax (Tmax) is 40 min (TG) vs. 30 min (TL), there is no significant difference between TG and TL either in their absorption constant (Ka) (0.123 vs. 0.138 min-1 respectively) or their distribution (a) (29.5 vs. 32.4 min) and elimination (beta) (6.3 vs. 6.6 h) half-lives (t1/2).",Comparative pharmacokinetics of temazepam Gelthix and liquid-filled soft gelatin capsules. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752914/),min,29.5,255880,DB00231,Temazepam
,1752914,distribution (a),"Although the mean Cmax for TG (616.6 ng/ml) is lower than for TL (707.9 ng/ml) and the median time to reach Cmax (Tmax) is 40 min (TG) vs. 30 min (TL), there is no significant difference between TG and TL either in their absorption constant (Ka) (0.123 vs. 0.138 min-1 respectively) or their distribution (a) (29.5 vs. 32.4 min) and elimination (beta) (6.3 vs. 6.6 h) half-lives (t1/2).",Comparative pharmacokinetics of temazepam Gelthix and liquid-filled soft gelatin capsules. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752914/),min,32.4,255881,DB00231,Temazepam
,1752914,elimination (beta),"Although the mean Cmax for TG (616.6 ng/ml) is lower than for TL (707.9 ng/ml) and the median time to reach Cmax (Tmax) is 40 min (TG) vs. 30 min (TL), there is no significant difference between TG and TL either in their absorption constant (Ka) (0.123 vs. 0.138 min-1 respectively) or their distribution (a) (29.5 vs. 32.4 min) and elimination (beta) (6.3 vs. 6.6 h) half-lives (t1/2).",Comparative pharmacokinetics of temazepam Gelthix and liquid-filled soft gelatin capsules. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752914/),h,6.3,255882,DB00231,Temazepam
,1752914,elimination (beta),"Although the mean Cmax for TG (616.6 ng/ml) is lower than for TL (707.9 ng/ml) and the median time to reach Cmax (Tmax) is 40 min (TG) vs. 30 min (TL), there is no significant difference between TG and TL either in their absorption constant (Ka) (0.123 vs. 0.138 min-1 respectively) or their distribution (a) (29.5 vs. 32.4 min) and elimination (beta) (6.3 vs. 6.6 h) half-lives (t1/2).",Comparative pharmacokinetics of temazepam Gelthix and liquid-filled soft gelatin capsules. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752914/),h,6.6,255883,DB00231,Temazepam
,2872062,elimination half-life,"The mean elimination half-life in the control subjects was 15.5 h, considerably longer than previous estimates.",The effects of age and chronic liver disease on the elimination of temazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872062/),h,15.5,260040,DB00231,Temazepam
,8329784,Tmax,"The 7.5-mg capsules reached peak plasma concentrations significantly faster than the 30-mg dosage form (mean Tmax 1.18 and 1.73 h, respectively; p = 0.01).",Bioavailability of temazepam: comparison of four 7.5-MG capsules with a single 30-MG capsule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329784/),h,1.18,273317,DB00231,Temazepam
,8329784,Tmax,"The 7.5-mg capsules reached peak plasma concentrations significantly faster than the 30-mg dosage form (mean Tmax 1.18 and 1.73 h, respectively; p = 0.01).",Bioavailability of temazepam: comparison of four 7.5-MG capsules with a single 30-MG capsule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329784/),h,1.73,273318,DB00231,Temazepam
